BD unveils fully automated molecular diagnostics platform in the U.S.

American medical technology company BD (Becton, Dickinson & Company) has reportedly announced the launch of a new fully automated, high-throughput platform in the U.S. catering to infectious disease molecular diagnostics.

The first test available on the new BD COR™ MX analytical tool adhering to the BD COR™ System is the molecular assay, BD CTGCTV2. It is a single test procedure that identifies three of the most common non-viral sexually transmitted infections (STIs).

These STIs include Neisseria gonorrhoeae (GC), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT), which have multiple adverse effects including pregnancy complications, increased susceptibility to HIV, and more.

Essentially, the new BD COR™ MX/PX System – with 510(k) clearance from the U.S. Food and Drug Administration – ensures a fully automated end-to-end molecular laboratory workflow, from processing the samples to deriving diagnostic test output for high-throughput labs.

For the unversed, the BD COR™ System helps lab technicians save time on specimen sorting and instead focus on other critical lab processes with its fully automated, scalable, and modular instrument designed to meet different laboratory needs like amplification of molecular testing volumes.

Well suited for laboratories, the BD COR™ System facilitates high throughput testing for driving innovative automation, reducing staff interaction, and enhancing laboratory workflow efficiencies.

Additionally, the system also consists of BD Onclarity™ HPV Assay instrument that uses extended genotyping for detecting HPV infections.

CE marked in 2021, the MX instrument, now available in the U.S. combined with the GX instrument boosts the use of platform and offers automated testing for a spectrum of high-demand, critical assays for women’s health and STI testing.

Benefits of BD COR™ MX/PX System

  • Comes with a loading capacity of 1,700 specimens with onboard capacity for samples and reagents and uninterrupted system processing for 7 hours.
  • Can deliver up to 1,000 sample outputs in 24 hours, eliminating the need for manual interactions.
  • Provides dual DBA targets for CT & GC detection at once in same sample and assay thereby reducing false positives.

Source Credit:


By Shreya Bhute

With corporate exposure in software and marketing, Shreya was always intrigued by content development. Having pursued her graduation in I.T. engineering, she works as a content writer for and jots down news articles across distinct domains including technology, business and healthcare.